Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
- Stoke Therapeutics will participate in a panel presentation at the 2023 Cantor Global Healthcare Conference
- None.
A live webcast of the presentation will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/ and can be accessed by following this Link. A replay of the webcast will be available for 30 days following the presentation.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~
View source version on businesswire.com: https://www.businesswire.com/news/home/20230921541026/en/
Stoke Investor Contact:
Eric Rojas
Vice President, Investor Relations
IR@stoketherapeutics.com
617-312-2754
Source: Stoke Therapeutics, Inc.